Emergency diagnostic tests

for cardio-vascular disease

Breakthrough MIAtek® technology

using magnetic nanoparticles

International publications

and strong patent protection

Committed to saving lives

and decreasing public health costs

A multidisciplinary team with strong experience and expertise

with a focus on the market

Magnisense, Dassault Systèmes and Roche discuss about the future of health, during the Women’s Forum organized at Deauville, October 2015.

Our Company

Our Company

Le Campus

Magnisense moved its R&D Lab to “Le Campus”, a new facility in Lyon, in the heart of the worldwide healthcare competitiveness cluster Lyon biopole. Its head office is located in the Paris based biomedical business cluster Medicen.

Le Campus

Magnisense, Emergency Diag to save lives.

Magnisense designs and develops proprietary diagnostic tests for cardio-vascular diseases, based on its patented breakthrough technology (MIAtek®). After several years of research and development, the final product is about to reach the market.


This mobile device uses consumables to enable medical practitioners to diagnose cardio-vascular events, especially heart attacks, in emergency situations. In just 15 minutes, the diagnostic test measures cardiac bio-markers directly from whole blood. The technology is protected by a ring fenced portfolio of 20+ worldwide patents.